Cdk2

Contents: Cdk2 (C16) Blocking Peptide
Catalog Number: 66-P709
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN₃ and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.

Prices for This Product*
Cat. No.	Size	Price	Qty	Action
66-P709-81	50 ug	$25

*International customers: Please contact your distributor for region specific pricing.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
66-P709	Blocking Peptides for anti-mouse/human/rat Cdk2 polyclonal	N/A	N/A	WB

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

This is a peptide mapping to the carboxy terminus of human Cdk2. Cyclin dependent kinases are key regulators of the progression of the cell cycle. Early in the cell cycle Cdk2, Cdk4, Cdk6 and their associated cyclins regulate the G1 to S phase transition (1, 2). Cdk2 plays a key role in the G1/S and S/G2 transitions through its associations with cyclin D1, cyclin D2, cyclin D3, cyclin E and cyclin A. Cdk4 also forms complexes with the D type cyclins, and is thought to regulate cell growth through the G1 phase of the cell cycle (3-6). The late stages of the cell cycle are regulated by another cyclin dependent kinase, Cdc2 p34. This kinase exists as a complex with both cyclin A and cyclin B. The best characterized of these associations is the Cdc2 p34-cyclin B complex that is required for the G2 to M phase transition (7,8).

Applications Reported

For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.

References

1. Ekholm SV, Reed SI. 2000. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biology 12(6): 676-684
2. Morisaki H, Ando A, Nagata Y, Pereira-Smith O, Smith JR, Ikeda K, Nakanishi M. 1999. Complex mechanisms underlying impaired activation of Cdk4 and Cdk2 in replicative senescence: roles of p16, p21, and cyclin D1. Exp Cell Research 253(2): 503-510.
3. Tong W, Pollard JW. 1999. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biology 19(3): 2251-64.
4. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. 1997. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 14(11): 1329-1340.
5. Chu CY, Lim RW. 2000. Involvement of p27(kip1) and cyclin D3 in the regulation of cdk2 activity during skeletal muscle differentiation. Biochimica Biophysica Acta 1497(2): 175-185.
6. Kishimoto T, Okumura E. In vivo regulation of the entry into M-phase: initial activation and nuclear translocation of cyclin B/Cdc2. 1997. Prog Cell Cycle Res 3:241-249.
7. Morla AO, Draetta G, Beach D, Wang JY. 1989. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell 58(1): 193-203.
8. O?Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, Longo DL, Kohn KW. 1993. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biological Chemistry 268(11): 8298-8308.

Related Products

Cat. 14-6709 Purified anti-mouse/human/rat Cdk2 polyclonal (clone Polyclonal)